Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in

Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in

Item

http://www.wikidata.org/entity/Q35011439

Q35011439

about

Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies Statins in heart failure: do we need another trial?Lipids, statins, and clinical outcomes in heart failure: rethinking the data.Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.Recent advances in preventing cardiovascular disorders by managing lipid levels.Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.Effect of CPAP treatment for obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis.CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.Early diagnosis of rats with acute myocardial infarction by measurement of brain natriuretic peptide.Five-year survival of patients with chronic systolic heart failure of ischemic and non-ischemic etiology: analysis of prognostic factors.Pleiotropic effects of the HMG-CoA reductase inhibitors NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-β receptor III expression.Effects of statins on cardiorenal syndrome.B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review.Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events Statins in heart failure: the paradox between large randomized clinical trials and real life.Current Perspectives on rosuvastatin.Treatment strategies for the prevention of heart failure Incorporating common biomarkers into the clinical management of heart failure Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA.The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease.Statins in heart failure-where do we stand?Biomarkers in advanced heart failure: diagnostic and therapeutic insights.Role of antithrombotic agents in heart failure.Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis.Clinical use of novel biomarkers in heart failure: towards personalized medicine.Natriuretic peptide-guided heart failure management.BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure.Incremental predictive value of natriuretic peptides for prognosis in the chronic stable heart failure population: a systematic review.New and emerging biomarkers in cardiovascular disease.Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients.Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Stud

P2860

Q24632679-7875810C-A881-4AB9-A835-EB4FCB6D5C05 Q26746907-04971309-75BC-42DC-B1EA-D6A4966133BD Q26998966-A1B300F4-1231-4C3C-B830-FAC836554663 Q30752824-855B1FFB-31C0-483C-A24F-D399DC9B7E2C Q33714463-2A688385-0D0C-42BF-92F4-6AE84CB0BF46 Q33908782-87FBD828-9C0B-4A3E-8266-8C4377A6ECA4 Q34269132-26204429-9640-447C-8327-1E9379AA2ECD Q34324771-19EAB629-FD71-4C4F-8029-F4BA0E4771ED Q34343533-328EA3CF-3200-47FF-BE3F-D5F99770E923 Q34429685-6E2EF699-B8E0-45FA-AA8A-6D757AE47F13 Q34542904-A926635E-B797-4070-8609-793E7A186095 Q34619812-F0384062-432B-4A7F-A667-AF0B91132482 Q34676067-F7EEC3F4-2B77-467D-B969-9FE4E93A30A1 Q34821843-BCCD8FD9-191F-46B3-921A-2C075C373263 Q34894749-BA0D763F-9B74-47DC-A00A-9AB57970D1D9 Q35051193-FAA4185C-AF7B-43F1-B76C-28DF269D87BB Q35206146-A54D15DC-13DD-4C43-A54A-A4058BFCAF47 Q35508766-C79E430B-3262-4882-B841-C80258088186 Q35750462-C0CD44F2-FCF3-49FE-8EC7-F4A9062DF67F Q35911736-9164DBC8-450E-4529-BA69-B8CF1A72CEDD Q36077149-FD1FBB8D-B5FE-42E7-B863-0445DD8BC4A2 Q36245755-970986EB-17DC-4E7F-98A7-7109995F5F75 Q36345739-9586E5A0-9C40-4B3C-B1B6-775CE4D5EA43 Q36522875-3E9F7AB5-20F9-4F5F-AA87-20E616427290 Q36796490-5C69AB98-B337-4A9E-8F74-A6E7C52CE491 Q37297198-E1C4A93C-760B-4518-B790-D589C7CAAE9B Q37347009-687E80B1-2CFE-4652-954C-F8AE25BF273F Q37495281-8D99A5BF-4ACD-4263-9D8C-A544158041DB Q37682793-AD8077BC-ACA9-44DB-86CD-5B5F89BB139F Q37817055-FB2B4E1E-574F-450F-95C3-17C8F6961068 Q37905948-4A0FC704-0907-49A0-B6D8-84722B2242A8 Q37998952-4274D13F-7131-4DF7-B4CF-338CDC762A34 Q38101731-784D2C48-B18D-4314-826E-A183C1ACE339 Q38109588-CF84A673-10A8-46E1-B3F6-2050913512F9 Q38161695-CD9B6AAF-2359-49D7-814E-54FCDE7CE675 Q38225445-8305DD06-F1BA-4BF9-BC0B-47DEC64BD864 Q38239624-BDF3BDF6-D219-46EE-9C0E-AFBAFC4ED055 Q38586900-99B39750-BE75-4351-AA74-569C7A08ADBE Q38622615-B1002E81-FDA3-4986-A9B9-41F23712247D Q38906411-DB26EAA0-0496-4787-90F8-00CA41F59F53

P2860

Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in

Item

http://www.wikidata.org/entity/Q35011439

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu